Acadia Pharmaceuticals is to begin a Phase I clinical study of AM-831, an innovative small molecule for the treatment of schizophrenia, in collaboration with Meiji Seika Pharma.

AM-831 combines muscarinic m1 partial agonism with both dopamine D2 and serotonin 5-HT2A antagonism.

The US Food and Drug Administration has reviewed the company’s investigational new drug application to advance the clinical development with AM-831.

The Phase I study is intended to evaluate the safety, tolerability and pharmacokinetics of the drug candidate in healthy volunteers and to help inform the design of future studies in patients with schizophrenia.

Acadia Pharmaceuticals CEO Uli Hacksell said that pre-clinical studies showed AM-831 to be the first antipsychotic drug to integrate both pro-cognitive and antipsychotic effects in schizophrenia patients.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.